Close Menu

IDT

Editas exclusively licensed the new enzyme, Alt-R Cas12a (Cpf1) Ultra, a mutant of Acidaminococcus sp. BV3L6 Cas12a (Cpf1), from IDT for therapeutic applications.

Early-access users have used IDT's rhAmpSeq technology to create genetic marker maps for plants and to validate off target events in gene editing.

 

CRISPR technology has made its way around the world, but in the wake of the He Jiankui controversy, the industry is asking what recourse it has against misuse.

The assay has been developed for research purposes, as a higher-throughput and lower-cost alternative to similar commercially available tests.

Within diagnostics, Beckman Coulter saw core revenue growth in the low-single digits, while Cepheid was up in the double digits for the quarter.

The company's Life Sciences segment was up 17 percent year over year, while its Diagnostics business grew 8 percent.

IDT will operate as a standalone company within Danaher's Life Sciences segment after the close of the deal, which is expected to occur in mid-2018.

Aldevron will manufacture IDT's patented S. pyogenes HiFi Cas9 mutant for research, clinical, and commercial uses.

The companies will develop a portfolio of indexed adapters specifically designed for multiplex NGS and optimized for use on Illumina systems such as the NovaSeq.

The agreement provides researchers with local customer care, and allows them to order reagents from within the country rather than importing them. 

Pages

The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.

There's increasing genetic evidence that a number of ancient hominins may have contributed to the human gene pool, according to Discover's The Crux blog.

The Japan News writes that Japan needs to seize the opportunity to ensure that a wide number of people benefit from personalized cancer treatments.

In Cell this week: messenger RNA expression and translation, RNA localization atlas, and more.